SAB BIO reports positive Phase 1 SAB-142 data: C-peptide preservation, T cell exhaustion, improved glycemic control

SAB Biotherapeutics, Inc.

All 4 T1D participants on SAB-142 2.5 mg/kg preserved C-peptide; 3 of 4 achieved super responder status with C-peptide above baseline at Day 120.
SAB-142 induced CD4+ Tconv cell exhaustion (TIGIT+ levels) correlating with C-peptide preservation, consistent with rabbit ATG mechanism.
Mean CGM time in range improved from 73% at baseline to 85% at Day 120, with no increase in exogenous insulin use.
Phase 2b SAFEGUARD trial topline data expected in 2H 2027; CEO cites potential best-in-class profile for T1D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.